Analysts Anticipate Aratana Therapeutics Inc (PETX) to Announce -$0.12 EPS

Finally, Acadian Asset Management LLC boosted its position in shares of Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset …

Aratana Therapeutics logoEquities research analysts expect Aratana Therapeutics Inc (NASDAQ:PETX) to report earnings of ($0.12) per share for the current quarter, according to Zacks. Three analysts have made estimates for Aratana Therapeutics’ earnings. The lowest EPS estimate is ($0.14) and the highest is ($0.10). Aratana Therapeutics reported earnings per share of ($0.19) in the same quarter last year, which would indicate a positive year over year growth rate of 36.8%. The company is scheduled to report its next quarterly earnings results on Tuesday, March 12th.

On average, analysts expect that Aratana Therapeutics will report full-year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.28) to ($0.23). For the next financial year, analysts expect that the firm will post earnings of ($0.22) per share, with EPS estimates ranging from ($0.32) to ($0.08). Zacks Investment Research’s EPS averages are an average based on a survey of research firms that cover Aratana Therapeutics.

Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.16) by $0.03. The company had revenue of $21.56 million for the quarter, compared to analysts’ expectations of $5.70 million. Aratana Therapeutics had a negative net margin of 52.94% and a negative return on equity of 15.08%.

PETX has been the subject of a number of recent analyst reports. HC Wainwright set a $10.00 target price on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Monday, November 5th. Stifel Nicolaus lowered Aratana Therapeutics from a “buy” rating to a “hold” rating and decreased their target price for the stock from $8.00 to $5.00 in a research report on Friday. BidaskClub raised Aratana Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, October 23rd. ValuEngine raised Aratana Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 22nd. Finally, TheStreet raised Aratana Therapeutics from a “d” rating to a “c-” rating in a research report on Wednesday, November 21st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $7.50.

Aratana Therapeutics stock traded down $1.58 during mid-day trading on Friday, reaching $4.37. The stock had a trading volume of 6,796,287 shares, compared to its average volume of 1,329,649. The stock has a market cap of $296.12 million, a price-to-earnings ratio of -4.51 and a beta of 1.78. Aratana Therapeutics has a one year low of $3.67 and a one year high of $7.16. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.17 and a quick ratio of 2.70.

In related news, insider Peter Steven St sold 11,513 shares of the business’s stock in a transaction that occurred on Tuesday, October 30th. The stock was sold at an average price of $5.86, for a total transaction of $67,466.18. Following the completion of the transaction, the insider now directly owns 562,720 shares in the company, valued at approximately $3,297,539.20. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Ernst Heinen sold 19,308 shares of the business’s stock in a transaction that occurred on Wednesday, November 7th. The shares were sold at an average price of $6.95, for a total value of $134,190.60. Following the transaction, the insider now owns 135,694 shares of the company’s stock, valued at $943,073.30. The disclosure for this sale can be found here. Insiders have sold a total of 77,607 shares of company stock valued at $476,116 in the last ninety days. Insiders own 5.30% of the company’s stock.

Several large investors have recently made changes to their positions in PETX. Hollencrest Capital Management bought a new position in shares of Aratana Therapeutics during the 4th quarter valued at approximately $153,000. American Century Companies Inc. bought a new position in shares of Aratana Therapeutics during the 2nd quarter valued at approximately $195,000. MetLife Investment Advisors LLC bought a new position in shares of Aratana Therapeutics during the 3rd quarter valued at approximately $215,000. Bank of Montreal Can boosted its position in shares of Aratana Therapeutics by 152.9% during the 3rd quarter. Bank of Montreal Can now owns 51,360 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 31,053 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its position in shares of Aratana Therapeutics by 69.8% during the 3rd quarter. Acadian Asset Management LLC now owns 194,746 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 80,064 shares during the last quarter. Institutional investors own 67.92% of the company’s stock.

About Aratana Therapeutics

Aratana Therapeutics, Inc, a pet therapeutics company, focuses on the licensing, development, and commercialization of therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics and therapeutic candidates in development consisting of small molecule pharmaceuticals and biologics.

Featured Article: NASDAQ

Get a free copy of the Zacks research report on Aratana Therapeutics (PETX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Aratana Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts